Loading
AH
Allied Healthcare Products Inc Stock: price and insider trades · United States
Allied Healthcare Products Inc: what insiders have been doing
We have very little insider data for Allied Healthcare Products Inc so far: the most recent filing dates from 30 November 2021. With so few records, no pattern can be drawn yet. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€521,207
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended June 2022 · cache
Analyst consensus
Income statement
RevenueUS$23.3M
Gross profitUS$2.2M9% margin
Net income-US$4.6M-19.8% margin
Last declaration on 30 November 2021
Declarations2 total
69,249 shares@ US$8.437100.0% of flowCommon StockSEC:0001415889-21-005587:0
52,972 sharesCommon StockSEC:0000904314-16-000009:0
2 of 2 declarations
About Allied Healthcare Products Inc
ALLIED HEALTHCARE PRODUCTS INC is a long-established U.S. medical-device company tied to the American market and historically associated with the NASDAQ exchange (United States). The company’s core business has centered on specialized healthcare equipment rather than broad, consumer-facing medtech. Its principal focus has been the design, manufacture, and sale of respiratory care products, medical gas equipment, and emergency medical products. The company’s headquarters are in St. Louis, Missouri, at 1720 Sublette Avenue, underscoring its industrial roots in the United States. SEC filings also show a portfolio of legacy brand names that have supported its market identity over time, including Allied Healthcare Products, Chemetron, Gomco, Oxequip, Lif-O-Gen, Life Support Products, Timeter, Vacutron, and Schuco. ([sec.gov](https://www.sec.gov/Archives/edgar/data/874710/000110465921120284/tm2128354d1_10k.htm?utm_source=openai))
From a business-model perspective, Allied served a specialized healthcare customer base that included hospitals, hospital equipment dealers, hospital construction contractors, home healthcare dealers, emergency medical products dealers, and other buyers of critical-care equipment. Its product lines were organized around three main categories: respiratory care, medical gas equipment, and emergency medical products. Within those categories, the company offered respiratory/anesthesia products, home respiratory care solutions, medical gas system construction products, gas regulation devices, disposable oxygen and specialty gas cylinders, portable suction equipment, and emergency respiratory/resuscitation and trauma/patient-handling products. That product mix positioned Allied as a niche supplier in mission-critical healthcare infrastructure, where product reliability and regulatory compliance matter more than scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/874710/000110465921120284/tm2128354d1_10k.htm?utm_source=openai))
Read moreShow less
Historically, Allied Healthcare Products built its franchise on specialized manufacturing and brand recognition rather than on volume dominance. Its competitive position was therefore shaped by technical know-how, long-standing relationships with healthcare distributors and institutional customers, and a product set aligned with essential clinical workflows. In a sector dominated by larger diversified medtech peers, Allied’s footprint was more concentrated and more operationally sensitive, which is typical for smaller U.S. medical-device manufacturers. ([cbinsights.com](https://www.cbinsights.com/company/allied-healthcare-products?utm_source=openai))
Recent developments are material for investors. In January 2023, the company disclosed a plan to dispose of all or substantially all of its assets and stated it did not intend to appeal Nasdaq’s delisting determination, with trading expected to be suspended on February 3, 2023. In May 2023, Allied filed for Chapter 11 protection in the United States and later entered into a stalking-horse asset purchase agreement for certain St. Louis-related business assets with Allied Medical, LLC. For investors monitoring SEC Form 4 insider transactions, these events are crucial context: the company’s recent story has been one of restructuring, asset monetization, and corporate transition rather than conventional organic expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/874710/000110465923006940/tm234514d1_ex99-1.htm?utm_source=openai))
